Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 72% below Graham Number ($29.65) — significant margin of safety
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -66.3%
DARIOHEALTH CORP. (DRIO) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $62 million . Key value metrics: P/E ratio 2.4, P/B ratio 0.91, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
DARIOHEALTH CORP. — Fundamental Analysis Summary
DARIOHEALTH CORP. (DRIO) is trading 72% below its Graham Number of $29.65 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.4x.
On financial health, DRIO shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -66.3% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.45.
StockPik's composite Value Score for DRIO is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DRIO shows earnings growing at 2%.